A5066378941- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA and protein synthesis mechanisms
- Acute Lymphoblastic Leukemia research
- RNA Research and Splicing
- Chronic Myeloid Leukemia Treatments
- RNA modifications and cancer
- Innovations in Medical Education
- Ion Transport and Channel Regulation
- Viral Infectious Diseases and Gene Expression in Insects
- Neuroscience and Neuropharmacology Research
- Medical Education and Admissions
- Protein Structure and Dynamics
- T-cell and B-cell Immunology
- Diversity and Career in Medicine
- Epigenetics and DNA Methylation
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Protein Degradation and Inhibitors
- Molecular Biology Techniques and Applications
University of Chicago
2010-2025
University of Illinois Chicago
2024
University of Chicago Medical Center
2020-2021
Twitter (United States)
2021
Alexandra Institute (Denmark)
2021
University of California, San Francisco
2019
Aarhus University
2002-2017
Harvard University
2015
Center for Systems Biology
2015
The renal cortical collecting duct (CCD) plays an important role in systemic acid-base homeostasis. β-intercalated cells secrete most of the HCO[Formula: see text], which is mediated by a luminal, DIDS-insensitive, Cl − /HCO[Formula: text] exchange. identity luminal exchanger matter debate. Anion isoform 4 (AE4) cloned from rabbit kidney was proposed to perform this function (Tsuganezawa H et al. J Biol Chem 276: 8180–8189, 2001). By contrast, it (Royaux IE Proc Natl Acad Sci USA 98:...
Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and classified as a favorable risk 2022 European LeukemiaNet (ELN) guidelines. The CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin (GO), commonly added to intensive chemotherapy (IC) in CBF-AML. We sought compare outcomes patients treated with IC without GO included 200 CBF-AML across seven academic centers. Induction treatment regimens were categorized alone,...
Abstract Current therapies for high-grade TP53 -mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of first-line (CR1) and outcomes, we assembled cohort 242 individuals with ≥10% blasts well-annotated clinical, molecular pathology data. Key outcomes examined were CR1 & 24-month (OS24). In this...
Therapy-related myeloid neoplasms (t-MNs) are a late complication of cytotoxic therapy and defined as distinct entity by the World Health Organization. While link between chemotherapy exposure risk subsequent t-MN is well-described, association radiation monotherapy (RT) less definitive. We analyzed 109 consecutive patients who developed t-MNs after RT describe latencies, cytogenetic profile, mutation analyses, clinical outcomes. The most common abnormality was clonal in chromosome 5 and/or...
We are creating a state-of-the-art 2D and 3D imaging atlas of zebrafish development. The employs both histology slides benchtop synchrotron micro CT results. Through this atlas, we expect to document normal abnormal organogenesis, reveal new levels structural detail, advance image informatics as form systems biology. has become widely used model organism in biological biomedical research for studies vertebrate development gene function. In work, will report on efforts optimize microCT...
The academic graduation season of 2022 marked the first, though seemingly not last, in which some residents completed their training with every year dominated by COVID-19 pandemic.As recent residency graduates meeting these criteria, we are struck how little know about practicing medicine a nonpandemic world.Virtual visits, high hospital censuses, and widespread understaffing were norm throughout our training, replacing many typical learning experiences.These changes hindered residents'...
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥ 10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of and outcomes, we assembled cohort 234 individuals with well-annotated clinical, molecular pathology data, evaluating CR1 & 24-month (OS24). In this elderly (median age 68.0 years) 73.4% receiving...